Real-World Effectiveness and Safety of Deucravacitinib for Adult Patients with Plaque Psoriasis: A 16-Week Multicenter Retrospective Study of Monotherapy and Combination Therapy
- 5 June 2026
- journal article
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in JapanJournal of Dermatological Treatment, 2024
- Deucravacitinib: First ApprovalDrugs, 2022
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trialJournal of the American Academy of Dermatology, 2022
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trialJournal of the American Academy of Dermatology, 2022